PDU CARB-X

CARB-X is a public-private partnership with the mission to advance research on antimicrobial resistance globally. The focus lies on innovative research and the development of novel antibacterial agents and therapies designed to counteract the rising burden of antimicrobial resistance. The following aspects are of central importance to this project: the product development unit (PDU) of the German Center for Infection Research (DZIF), together with the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute (PEI) act as so-called CARB-X accelerator. They are at the disposal of applicants and projects for scientific-regulatory questions. Further they advise and accompany researchers on their way to a potential CARB-X funding. BfArM and PEI especially support this process with regard to regulatory questions in the context of scientific consulting events as well as in the implementation of trainings. This project combines different phases: the phase of the discovery of new therapeutic approaches, their pharmaceutical and preclinical development, as well as clinical trials.